Webinar: Redefining Excellence in the Era of AI and Human Collaboration
Discover your potential savings with our ROI Calculator
Webinar: Elevating Customer Experience Through Quality
Self-guided Product Tours
Product Demo Videos
Pricing
Recent Analyst Insights
Featured Analyst Insights
2026 Gartner® Magic Quadrant™ for Quality Management System Software
Recent Blogs
Recent Infographics
Recent Case Studies
Featured Case Study
ComplianceQuest Medical Devices QMS Success Stories eBook
Recent Checklists
Featured Checklist
Complaint Handling Process for MedTech and Life Science Companies
Course Offerings
Recent CQ Guides
Datasheets
Brochures
Demo Center
Videos
Podcasts
Recent Webinars
Webinar
Unlocking the Value of Complaints
Recent Whitepapers
Whitepaper
Why You Need to Digitally Transform Your QMS
Compliance
Toolkits
Infographic
Safety Technology Trends to Watch in 2023 (Infographic)
Recent Toolkits
Events and Webinars
Events
Upcoming Webinars
Featured Event
PDA/FDA Joint Regulatory Conference 2026
14 Sep, 2026
Washington, DC
About
About ComplianceQuest
ComplianceQuest is the #1 AI-powered Quality, Risk, and Compliance (QRC) platform that connects Product, Quality, Manufacturing, People, Suppliers and Customers in a single system.
Built on Salesforce, the platform delivers end-to-end visibility, AI-driven intelligence, and enterprise-scale execution, enabling organizations to manage risk, ensure regulatory compliance, and turn quality into a driver of growth.
Meet the Leadership Team
Careers
Where Your Career Takes Flight: Join our dynamic team and be part of an innovative, collaborative and rewarding workplace culture.
Corporate Citizenship
Impact Through Action: How the ComplianceQuest team supports social causes and community engagement
Customers & Testimonials
Newsroom
The Pulse of ComplianceQuest: Our newsroom shares stories of innovation, progress, and change
Partners
Stronger Together: How our partnerships drive success and innovation
Upcoming Events
In 2018, the US FDA had announced its plans to harmonize FDA Quality System Regulations (QSR) with ISO 13485:2016 quality system requirements for medical device registrants. This initiative was proposed to increase the alignment of the US market’s pathway more closely with other major device markets.
Taking it a step forward, in 2022, the FDA announced the proposed rule for aligning the current good manufacturing practice (cGMP) requirements of the QSR with ISO 13485:2016. This will further the cause of harmonization, though it will also introduce new challenges.
ISO 13485 is an international standard that the medical devices companies with a global presence are already compliant with. For the US market, they had an additional requirement of being compliant with the FDA’s QSR. By harmonizing the QSR with the ISO requirement, the FDA is attempting to eliminate the duplicative regulatory requirement that acts as an impediment to market access.
For Medical Device Quality Management Systems, ISO 13485 is a comprehensive standard that elucidates the best practices to be followed to ensure medical device product safety and quality. By aligning with this standard that is de facto in the rest of the world, FDA will pave the way for greater efficiency in the medical device manufacturing companies without compromising on quality.
As part of the proposal, there will be changes to FDA Part 820. While some existing rules will be removed, some new rules drawn from the ISO 13485 will be added. The new additions to Part 820 include:
These additions draw heavily from ISO 13485 to ensure as close an alignment as possible. Among the additions, Section 820.45 will be of special significance since the FDA has elaborated in great detail the requirements for labeling and packaging.
Every year, improper labeling and packaging have been found to be one of the major causes of a large number of device recalls. For instance, in Q3 of 2021, 36 device recalls were due to mislabeling issues. This came in second after software issues.
Since ISO 13485 requirements for inspection of packaging and labeling seem to be insufficient to meet quality needs, FDA has introduced Section 820.45 supplement ISO 13485:2016 in this aspect.
The medical device industry will have to transition to the new QSR, but the good news is that FDA is giving a year for the transition after the regulations are finalized. The industry representatives have sought a two-year transition period, the decision on which is still pending . During this period, the US-only companies will have to familiarize themselves with ISO 13485:2016.
According to a Preliminary Regulatory Impact Analysis done by the FDA for this proposed rule, nearly 4,445 companies currently are not compliant with ISO 13485. While this may seem like a redundant regulatory step for such companies, compliance with the new regulation and harmonization will make globalization much easier at a later stage.
FDA uses the Quality System Inspection Technique (QSIT) to inspect medical device companies. Apart from the medical device manufacturers, the FDA is also introducing changes to how inspection of these companies will be regulated, aligning it with the ISO 13485 standard. There will be time given for this transition as well, giving inspectors time to make themselves familiar with ISO 13485.
While FDA will not be issuing ISO 13485 certifications, such a certification will not exempt a company from inspections. Inspection techniques will have to evolve to meet the new requirements. As of now, the rules are still in the proposal stage and will likely undergo many changes before they are firmed up and introduced. But in the meantime, manufacturers should invest time and effort to understand the likely impact of ISO 13485 on the QMS.
As technologies evolve, so do regulations to keep pace. Compliance is only one aspect of these regulations. By improving the processes to comply with the new regulatory needs, businesses can also ensure the development of quality medical devices. The harmonization with global standards will help medical device manufacturers with complying with global standards with ease, establish a global presence with fewer hassles, and improve the speed of alignment at lesser effort, cost and time.
It is too premature to talk about changing the quality management system of your organization to meet the proposed changes. However, automated quality management systems such as the one from ComplianceQuest can make the process smooth, easy, and efficient. The ComplianceQuest cloud-based EQMS is already aligned with the ISO standards. It also enables introducing global changes with simple customization capabilities.
As a result, the transition to a new system will become simpler, seamless, and applicable across the organization in different geographic locations.
Change management is a critical feature of the CQ solution that enables managing changes for a smooth transition. Inspection management can help schedule inspections, implement the new rules, and make businesses inspection ready. Document management will be another key aspect in handling the transition, documenting processes, making them easily accessible at the time of inspections, and submitting regulatory reports. Managing these aspects manually or using a legacy system will be inefficient and counterproductive.
Be future-ready with the cloud-based flexible and scalable EQMS from ComplianceQuest and meet regulatory requirements and changes with the least disruption to business processes. To know more about the CQ solution, visit: https://www.compliancequest.com/
Ask for a demo: https://www.compliancequest.com/online-demo/
Contact us now: https://www.compliancequest.com/contact-us/
Learn about all features of our Product, Quality, Safety, and Supplier suites. Please fill the form below to access our comprehensive Demo Video.
Please confirm your details
By submitting this form you agree that we can store and process your personal data as per our Privacy Statement. We will never sell your personal information to any third party.
Enter Captcha
According to FDA 21 CFR Part 820.70(i), any software used to automate any part of…
On January 31, 2024, the US Food and Drug Administration announced an amendment to 21…